First-Line Avelumab Plus Axitinib vs Sunitinib in Patients With Advanced Renal Cell Carcinoma
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
Disclosure statements are available on the authors' profiles:
Updated Efficacy Results From the JAVELIN Renal 101 Trial: First-Line Avelumab Plus Axitinib Versus Sunitinib in Patients With Advanced Renal Cell Carcinoma
Ann. Oncol 2020 Apr 24;[EPub Ahead of Print], TK Choueiri, RJ Motzer, BI Rini, J Haanen, MT Campbell, B Venugopal, C Kollmannsberger, G Gravis-Mescam, M Uemura, JL Lee, MO Grimm, H Gurney, M Schmidinger, J Larkin, MB Atkins, SK Pal, J Wang, M Mariani, S Krishnaswami, P Cislo, A Chudnovsky, C Fowst, B Huang, A di Pietro, L AlbigesFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.